Relation between iron status and hemoglobin in hepatitis patient with diabetes undergo hemodialysis

2022 ◽  
Author(s):  
Rusul Arif Abd Ali ◽  
Zahraa Kareem Al-Mayali ◽  
Wijdan Rajh Hamza Al-Kraity

Diabetes mellitus can be defined as chronic metabolic disease which results from either relative or complete absence of insulin by the pancreatic beta islet cells. This in-turn may lead to hyperglycemia due to disturbances in the metabolism of glucose. In the human body, iron is con- sidered to be an effective pro-oxidant and participates in the generation of reactive oxygen species (ROS) such as hydroxyl radical. Because of the poor antioxidant defense mechanism of beta cells (low production of antioxidant enzymes such as catalase, glutathione peroxidase and dismutase), so they are highly prone to iron-induced oxidative stress and iron deposition in it and this will lead to apoptosis, and subsequently insulin deficiency. This iron deposition in beta cells will also lead to insulin resistance by reducing insulin extracting ability of the liver and inhibiting glucose uptake in muscle tissues and fats, this in turn will result in high production of hepatic glucose. Ferritin which is an acute phase reactant protein, that responds to acute stress like trauma, infections, tissue necrosis and surgery, it can produce diabetes mellitus either through inflammation or by increasing iron stores.


2007 ◽  
Vol 15 (1) ◽  
Author(s):  
K Basher ◽  
K Deb
Keyword(s):  

2008 ◽  
Vol 4 (4) ◽  
pp. 365-370 ◽  
Author(s):  
S. Ounjaijean ◽  
C. Thephinlap ◽  
U. Khansuwan ◽  
C. Phisalapong ◽  
S. Fucharoen ◽  
...  

2019 ◽  
Vol 14 (3) ◽  
pp. 203-208
Author(s):  
Evan Noori Hameed ◽  
Haydar F. Hadi AL Tukmagi ◽  
Hayder Ch Assad Allami

Background: Inadequate response to Erythropoietin Stimulating Agents (ESA) despite using relatively larger doses regimen represents a potential risk factor of Cardiovascular (CV) related mortality in addition to health-care economic problems in anemic patients with Chronic Kidney Disease (CKD). Erythropoietin (EPO) hyporesponsiveness related to inflammation has been increased progressively. Melatonin is well known as a potent anti-inflammatory agent. Therefore, the current study was designed to evaluate whether melatonin could improve anemic patients response to EPO. Methods: This single controlled clinical study was carried out in 41 CKD patients with hemoglobin (Hb) levels less than 11g/dl divided randomly in a 1:1 ratio into 2 groups; treatment group who received 5mg melatonin plus their regular treatments and control group who received their regular treatments only. Hematological and iron status parameters include Hb level, serum iron (S. iron), Transferrin Saturation Ratio (TSAT) and serum ferritin (S. ferritin) in addition to inflammatory parameters that include tissue necrotic factor alfa (TNF-α), interleukin-1beta (IL-1β) and interleukin-6 (IL-6) determined before and after 12 weeks of treatment. Results: Melatonin remarkably increases the Hb level with a significant increase in S. iron and TSAT compared to baseline. The elevation of S. iron and TSAT was significantly higher in the melatonin group. Additionally, all inflammatory markers estimated were reduced significantly by melatonin compared to base line and control group. Conclusion: The results of the current study showed that melatonin has an advantageous effect on improving EPO response in anemic patients with CKD.


2007 ◽  
Vol 83 (4) ◽  
pp. 370-376 ◽  
Author(s):  
Ana Cláudia F. Vieira ◽  
Alcides S. Diniz ◽  
Poliana C. Cabral ◽  
Rejane S. Oliveira ◽  
Margarida M. F. Lóla ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document